药代-话题@MedSci

#药代#

158篇内容 | 1442人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1666647, encodeId=a3b8166664e9c, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, objectTitle=药代备案刻不容缓上海食药监局联手卫计委强化管理, objectType=article, longId=92404, objectId=33469240461, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=33469240461, replyNumber=0, likeNumber=32, createdTime=2018-02-15, rootId=0, userName=fengyqf, userId=bccf26064950, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=33469240461, moduleTitle=药代备案刻不容缓上海食药监局联手卫计委强化管理, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=33469240461)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666649, encodeId=a12616666496b, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, objectTitle=从医药代表的被迫转型看一颗药的奇幻之旅, objectType=article, longId=94851, objectId=1687948514d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1687948514d, replyNumber=0, likeNumber=27, createdTime=2017-06-02, rootId=0, userName=fengyqf, userId=bccf26064950, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1687948514d, moduleTitle=从医药代表的被迫转型看一颗药的奇幻之旅, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1687948514d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666643, encodeId=503c166664348, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, objectTitle=评论丨300万医药代表流行着一种“职业病” 治得了吗？, objectType=article, longId=88732, objectId=b42888e326e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b42888e326e, replyNumber=0, likeNumber=37, createdTime=2017-12-14, rootId=0, userName=fengyqf, userId=bccf26064950, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b42888e326e, moduleTitle=评论丨300万医药代表流行着一种“职业病” 治得了吗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b42888e326e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666636, encodeId=31221666636e7, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, objectTitle=王志安：医药代表在中国的成长变迁史, objectType=article, longId=86276, objectId=bec8862e60f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bec8862e60f, replyNumber=0, likeNumber=21, createdTime=2017-05-12, rootId=0, userName=fengyqf, userId=bccf26064950, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bec8862e60f, moduleTitle=王志安：医药代表在中国的成长变迁史, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bec8862e60f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666634, encodeId=29091666634d7, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, objectTitle=女医生深夜独自值班，遭医药代表抢劫猥亵！, objectType=article, longId=77861, objectId=bbd4e786119, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bbd4e786119, replyNumber=0, likeNumber=23, createdTime=2016-10-19, rootId=0, userName=fengyqf, userId=bccf26064950, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bbd4e786119, moduleTitle=女医生深夜独自值班，遭医药代表抢劫猥亵！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bbd4e786119)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666633, encodeId=7a0d1666633b0, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, objectTitle=J Acq Immun Def Synd：Dolutegravir对二甲双胍药代动力学的影响研究, objectType=article, longId=66123, objectId=e4cb6612395, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e4cb6612395, replyNumber=0, likeNumber=35, createdTime=2016-05-24, rootId=0, userName=fengyqf, userId=bccf26064950, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e4cb6612395, moduleTitle=J Acq Immun Def Synd：Dolutegravir对二甲双胍药代动力学的影响研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e4cb6612395)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666631, encodeId=bc8916666319a, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, objectTitle=DRCP：亚洲2型糖尿病患者利拉鲁肽的药代动力学和剂量暴露反应的联系, objectType=article, longId=47740, objectId=d2704e740fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d2704e740fd, replyNumber=0, likeNumber=33, createdTime=2015-07-17, rootId=0, userName=fengyqf, userId=bccf26064950, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d2704e740fd, moduleTitle=DRCP：亚洲2型糖尿病患者利拉鲁肽的药代动力学和剂量暴露反应的联系, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d2704e740fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666632, encodeId=d6ee166663269, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, objectTitle=Invest New Drugs：dacomitinib(pan-HER 抑制剂)用于晚期头颈部鳞状细胞癌的药代动力学评价, objectType=article, longId=50462, objectId=d8575046299, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d8575046299, replyNumber=0, likeNumber=31, createdTime=2015-11-01, rootId=0, userName=fengyqf, userId=bccf26064950, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d8575046299, moduleTitle=Invest New Drugs：dacomitinib(pan-HER 抑制剂)用于晚期头颈部鳞状细胞癌的药代动力学评价, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d8575046299)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666630, encodeId=c6aa16666303e, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, objectTitle=南方医大珠江医院开除与医药代表接触的医生, objectType=article, longId=43024, objectId=dfcd4302404, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dfcd4302404, replyNumber=0, likeNumber=25, createdTime=2015-08-15, rootId=0, userName=fengyqf, userId=bccf26064950, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dfcd4302404, moduleTitle=南方医大珠江医院开除与医药代表接触的医生, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dfcd4302404)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666628, encodeId=eb8b166662838, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, objectTitle=临床药代动力学试验的常见设计类型与统计分析, objectType=article, longId=34682, objectId=0673346820f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0673346820f, replyNumber=0, likeNumber=34, createdTime=2014-06-18, rootId=0, userName=fengyqf, userId=bccf26064950, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0673346820f, moduleTitle=临床药代动力学试验的常见设计类型与统计分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0673346820f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666627, encodeId=edea166662e51, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, objectTitle=CCP：研究发现阿法替尼群体药代动力学新模型, objectType=article, longId=34275, objectId=5bdc342e5e9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5bdc342e5e9, replyNumber=0, likeNumber=30, createdTime=2015-01-04, rootId=0, userName=fengyqf, userId=bccf26064950, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5bdc342e5e9, moduleTitle=CCP：研究发现阿法替尼群体药代动力学新模型, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5bdc342e5e9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666625, encodeId=fc3316666251d, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, objectTitle=EMEA关于肝功能损害病人的药代动力学评价指南, objectType=article, longId=31895, objectId=d464318956c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d464318956c, replyNumber=0, likeNumber=35, createdTime=2014-08-25, rootId=0, userName=fengyqf, userId=bccf26064950, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d464318956c, moduleTitle=EMEA关于肝功能损害病人的药代动力学评价指南, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d464318956c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666629, encodeId=98a216666297f, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, objectTitle=ASCO 2014：5-FU和顺铂治疗晚期鼻咽癌的药代动力学和遗传药理学分析, objectType=article, longId=35644, objectId=12f33564411, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=12f33564411, replyNumber=0, likeNumber=35, createdTime=2015-01-20, rootId=0, userName=fengyqf, userId=bccf26064950, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=12f33564411, moduleTitle=ASCO 2014：5-FU和顺铂治疗晚期鼻咽癌的药代动力学和遗传药理学分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=12f33564411)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666626, encodeId=7ff01666626b4, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, objectTitle=EMEA关于肾功能损害病人药代动力学评价指南说明, objectType=article, longId=31896, objectId=614931896eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=614931896eb, replyNumber=0, likeNumber=35, createdTime=2014-11-07, rootId=0, userName=fengyqf, userId=bccf26064950, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=614931896eb, moduleTitle=EMEA关于肾功能损害病人药代动力学评价指南说明, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=614931896eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666624, encodeId=35fa16666241c, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, objectTitle=医药代表吐槽：新药研发审批存瓶颈新药过审成旧药, objectType=article, longId=31773, objectId=efe031e73d7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=efe031e73d7, replyNumber=0, likeNumber=29, createdTime=2014-06-07, rootId=0, userName=fengyqf, userId=bccf26064950, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=efe031e73d7, moduleTitle=医药代表吐槽：新药研发审批存瓶颈新药过审成旧药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=efe031e73d7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666622, encodeId=28f5166662205, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, objectTitle=葛兰素史克取消医药代表销售目标, objectType=article, longId=28237, objectId=edb12823e1c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=edb12823e1c, replyNumber=0, likeNumber=34, createdTime=2014-01-10, rootId=0, userName=爆笑小医, userId=395f25, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=edb12823e1c, moduleTitle=葛兰素史克取消医药代表销售目标, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=edb12823e1c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666623, encodeId=29341666623d9, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, objectTitle=甘李药业7名药代涉商业贿赂被批捕医生退赃数百万, objectType=article, longId=29249, objectId=1ee429249a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1ee429249a7, replyNumber=0, likeNumber=29, createdTime=2014-04-09, rootId=0, userName=fengyqf, userId=bccf26064950, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1ee429249a7, moduleTitle=甘李药业7名药代涉商业贿赂被批捕医生退赃数百万, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1ee429249a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1666621, encodeId=5b711666621e7, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, objectTitle=Trimel公司Tefina药代动力学研究结果发布, objectType=article, longId=5762, objectId=954c5e624c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=954c5e624c, replyNumber=0, likeNumber=21, createdTime=2013-04-10, rootId=0, userName=fengyqf, userId=bccf26064950, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=954c5e624c, moduleTitle=Trimel公司Tefina药代动力学研究结果发布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=954c5e624c)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

药代

2020-05-29

fengyqf (审核中...)

前往app查看评论内容

#药代#

药代备案刻不容缓上海食药监局联手卫计委强化管理

2018-02-15

fengyqf (审核中...)

前往app查看评论内容

#药代#

从医药代表的被迫转型看一颗药的奇幻之旅

2017-06-02

fengyqf (审核中...)

前往app查看评论内容

#药代#

评论丨300万医药代表流行着一种“职业病” 治得了吗？

2017-12-14

fengyqf (审核中...)

前往app查看评论内容

#药代#

王志安：医药代表在中国的成长变迁史

2017-05-12

fengyqf (审核中...)

前往app查看评论内容

#药代#

女医生深夜独自值班，遭医药代表抢劫猥亵！

2016-10-19

fengyqf (审核中...)

前往app查看评论内容

#药代#

J Acq Immun Def Synd：Dolutegravir对二甲双胍药代动力学的影响研究

2016-05-24

fengyqf (审核中...)

前往app查看评论内容

#药代#

DRCP：亚洲2型糖尿病患者利拉鲁肽的药代动力学和剂量暴露反应的联系

2015-07-17

fengyqf (审核中...)

前往app查看评论内容

#药代#

Invest New Drugs：dacomitinib(pan-HER 抑制剂)用于晚期头颈部鳞状细胞癌的药代动力学评价

2015-11-01

fengyqf (审核中...)

前往app查看评论内容

#药代#

南方医大珠江医院开除与医药代表接触的医生

2015-08-15

fengyqf (审核中...)

前往app查看评论内容

#药代#

临床药代动力学试验的常见设计类型与统计分析

2014-06-18

fengyqf (审核中...)

前往app查看评论内容

#药代#

CCP：研究发现阿法替尼群体药代动力学新模型

2015-01-04

fengyqf (审核中...)

前往app查看评论内容

#药代#

EMEA关于肝功能损害病人的药代动力学评价指南

2014-08-25

fengyqf (审核中...)

前往app查看评论内容

#药代#

ASCO 2014：5-FU和顺铂治疗晚期鼻咽癌的药代动力学和遗传药理学分析

2015-01-20

fengyqf (审核中...)

前往app查看评论内容

#药代#

EMEA关于肾功能损害病人药代动力学评价指南说明

2014-11-07

fengyqf (审核中...)

前往app查看评论内容

#药代#

医药代表吐槽：新药研发审批存瓶颈新药过审成旧药

2014-06-07

爆笑小医 (审核中...)

前往app查看评论内容

#药代#

葛兰素史克取消医药代表销售目标

2014-01-10

fengyqf (审核中...)

前往app查看评论内容

#药代#

甘李药业7名药代涉商业贿赂被批捕医生退赃数百万

2014-04-09

fengyqf (审核中...)

前往app查看评论内容

#药代#

Trimel公司Tefina药代动力学研究结果发布

2013-04-10

科室
- - 订阅+
  - 更多科室
工具
服务